Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutati...

王婷，马惠文，王东林，李代蓉，余慧青… - 现代生物医学 …, 2018 - biomed.cnjournals.com

摘要目的: 研究化疗和靶向治疗对EGFR 基因21 外显子L858R 突变肺腺癌患者的临床疗效和
患者生存率的影响. 方法: 选择2012 年1 月~ 2016 年1 月在重庆市肿瘤医院治疗的95 例EGFR …

[HTML][HTML] Methylenetetrahydrofolate reductase C677T (rs1801133) polymorphism and pemetrexed treatment outcome in patients with non–small-cell lung cancer

MH Abbasian, N Ansarinejad, T Ramim… - Personalized Medicine …, 2021 - pmjournal.ir

Background: Lung cancer is the first cause of cancer deaths in the world. Pemetrexed is an
antifolate drug used as a first or second-line in the treatment of advanced non-small cell lung …

被引用次数：1 相关文章

[引用][C] 替吉奥联合康艾注射液治疗晚期非小细胞肺癌的效果与预后因素分析

杨君，韩莹，郭晓辉，汪力慧 - 中国医药导报, 2016

Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib

AC McGrath, G Sandhu, E Walpole… - Anti-Cancer …, 2018 - journals.lww.com

Erlotinib is used to treat non-small-cell lung cancer (NSCLC). Erlotinib was subsidized on
the Pharmaceutical Benefits Schedule in Australia for the treatment of advanced stage (IIIB …

被引用次数：2 相关文章所有 5 个版本

[HTML] cyberleninka.ru

[HTML][HTML] Пятилетние результаты применения ниволумаба у больных с метастатическим немелкоклеточным раком легкого в реальной клинической практике …

ДИ Юдин, КК Лактионов, КА Саранцева… - Медицинский …, 2021 - cyberleninka.ru

Введение. Рак легкого остается одним из наиболее распространенных и смертельных
онкологических заболеваний в мире. Долгое время химиотерапия оставалась …

Apatinib Plus Vinorelbine in Second Line Treatment Failure Wildtype Advanced Non-Small Cell Lung Cancer (VICTOR): A Phase II Three-Dimensional Co-Culture …

X Zhang, Y Xiong, Q Xia, F Wu, L Liu, Y Zhou, L Zeng… - 2019 - papers.ssrn.com

Background: We aimed to assess the efficacy and safety of apatinib combined with oral
vinorelbine in these patients using a prospective three-dimensional co-culture platform …